Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Abstract

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).

Keywords

AxitinibAvelumabSunitinibRenal cell carcinomaMedicineInternal medicineOncologyCarcinomaUrologyImmunotherapyNivolumabCancer

MeSH Terms

AdministrationIntravenousAdultAgedAged80 and overAntibodiesMonoclonalAntibodiesMonoclonalHumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAxitinibCarcinomaRenal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedProgrammed Cell Death 1 ReceptorProgression-Free SurvivalSingle-Blind MethodSunitinibSurvival Rate

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Publication Info

Year: 2019
Type: article
Volume: 380
Issue: 12
Pages: 1103-1115
Citations: 2439
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2439

OpenAlex

Influential

2075

CrossRef

Cite This

APA Style

                            
                                
                                    Balaji Venugopal, 
                                
                                    Christian Kollmannsberger, 
                                
                                    Sylvie Négrier
                                
                                et al.
                            
                            (2019). 
                            Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. 
                            New England Journal of Medicine
                            , 380
                            (12)
                            , 1103-1115.
                            https://doi.org/10.1056/nejmoa1816047
                        

Identifiers

DOI: 10.1056/nejmoa1816047
PMID: 30779531
PMCID: PMC6716603

Data Quality

Data completeness: 90%